Cargando…
Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma
Anti-vascular endothelial growth factor (anti-VEGF) drugs have long been the only first-line treatment for advanced or unresectable hepatocellular carcinoma (HCC). Recently, the combination of bevacizumab (an anti-VEGF drug) and atezolizumab (an immune checkpoint blockade, ICB) has been proven to ha...
Autores principales: | Liu, Ze-Long, Zhu, Ling-Ling, Liu, Jing-Hua, Pu, Zhang-Ya, Ruan, Zhi-Ping, Chen, Jiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803564/ https://www.ncbi.nlm.nih.gov/pubmed/33223512 http://dx.doi.org/10.18632/aging.104119 |
Ejemplares similares
-
Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor
por: Xie, Qing-Yun, et al.
Publicado: (2022) -
Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma
por: Nakao, Keisuke, et al.
Publicado: (2015) -
Vascular endothelial growth factor A is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma
por: Qi, Yuchen, et al.
Publicado: (2023) -
Serum vascular endothelial growth factors C and D as forecast tools for patients with gallbladder carcinoma
por: Liu, Min-Chao, et al.
Publicado: (2015) -
Downregulation of Vascular Endothelial Growth Factor
Enhances Chemosensitivity by Induction of Apoptosis
in Hepatocellular Carcinoma Cells
por: Chinh Chung, Doan, et al.
Publicado: (2015)